{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T17:08:47Z","timestamp":1795108127893,"version":"4.10.3"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clear-cell carcinomas (CCCs) are a histological group of highly aggressive malignancies commonly originating in the kidney and ovary. CCCs are distinguished by aberrant lipid and glycogen accumulation and are refractory to a broad range of anti-cancer therapies. Here we identify an intrinsic vulnerability to ferroptosis associated with the unique metabolic state in CCCs. This vulnerability transcends lineage and genetic landscape, and can be exploited by inhibiting glutathione peroxidase 4 (GPX4) with small-molecules. Using CRISPR screening and lipidomic profiling, we identify the hypoxia-inducible factor (HIF) pathway as a driver of this vulnerability. In renal CCCs, HIF-2\u03b1 selectively enriches polyunsaturated lipids, the rate-limiting substrates for lipid peroxidation, by activating the expression of hypoxia-inducible, lipid droplet-associated protein (<jats:italic>HILPDA<\/jats:italic>). Our study suggests targeting GPX4 as a therapeutic opportunity in CCCs, and highlights that therapeutic approaches can be identified on the basis of cell states manifested by morphological and metabolic features in hard-to-treat cancers.<\/jats:p>","DOI":"10.1038\/s41467-019-09277-9","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T10:04:10Z","timestamp":1554717850000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":847,"title":["A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis"],"prefix":"10.1038","volume":"10","author":[{"given":"Yilong","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Palte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy A.","family":"Deik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4633-5546","authenticated-orcid":false,"given":"John K.","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuen-Yi","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9143-6296","authenticated-orcid":false,"given":"Rebecca","family":"Deasy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kost-Alimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Dan\u010d\u00edk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizaveta S.","family":"Leshchiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasanthi S.","family":"Viswanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Signoretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6795-6336","authenticated-orcid":false,"given":"Jesse S.","family":"Boehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget K.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3707-9889","authenticated-orcid":false,"given":"John G.","family":"Doench","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8259-9245","authenticated-orcid":false,"given":"Clary B.","family":"Clish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1800-5112","authenticated-orcid":false,"given":"Paul A.","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1922-7558","authenticated-orcid":false,"given":"Stuart L.","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"key":"9277_CR1","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMra1601333","volume":"376","author":"TK Choueiri","year":"2017","unstructured":"Choueiri, T. K. & Motzer, R. J. Systemic therapy for metastatic renal-cell carcinoma. N. Engl. J. Med. 376, 354\u2013366 (2017).","journal-title":"N. Engl. J. Med."},{"key":"9277_CR2","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5","volume":"88","author":"T Sugiyama","year":"2000","unstructured":"Sugiyama, T. et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88, 2584\u20132589 (2000).","journal-title":"Cancer"},{"key":"9277_CR3","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1097\/IGC.0000000000000297","volume":"24","author":"K Hasegawa","year":"2014","unstructured":"Hasegawa, K. et al. Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix. Int. J. Gynecol. Cancer.: Off. J. Int. Gynecol. Cancer. Soc. 24, S90\u2013S95 (2014).","journal-title":"Int. J. Gynecol. Cancer.: Off. J. Int. Gynecol. Cancer. Soc."},{"key":"9277_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1365-2559.1986.tb02462.x","volume":"10","author":"S Schroder","year":"1986","unstructured":"Schroder, S. & Bocker, W. Clear-cell carcinomas of thyroid gland: a clinicopathological study of 13 cases. Histopathology 10, 75\u201389 (1986).","journal-title":"Histopathology"},{"key":"9277_CR5","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/S1499-3872(17)60071-7","volume":"16","author":"P Bannasch","year":"2017","unstructured":"Bannasch, P., Ribback, S., Su, Q. & Mayer, D. Clear cell hepatocellular carcinoma: origin, metabolic traits and fate of glycogenotic clear and ground glass cells. Hepatobiliary & Pancreat. Dis. INT.: HBPD INT 16, 570\u2013594 (2017).","journal-title":"Hepatobiliary & Pancreat. Dis. INT.: HBPD INT"},{"key":"9277_CR6","doi-asserted-by":"crossref","first-page":"773","DOI":"10.4103\/0973-1482.136043","volume":"10","author":"Y Modi","year":"2014","unstructured":"Modi, Y. et al. Primary clear cell ductal adenocarcinoma of the pancreas: a case report and clinicopathologic literature review. J. Cancer Res. Ther. 10, 773\u2013776 (2014).","journal-title":"J. Cancer Res. Ther."},{"key":"9277_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJMoa1505917","volume":"374","author":"WM Linehan","year":"2016","unstructured":"Linehan, W. M. et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N. Engl. J. Med. 374, 135\u2013145 (2016).","journal-title":"N. Engl. J. Med."},{"key":"9277_CR8","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/nrneph.2017.59","volume":"13","author":"HI Wettersten","year":"2017","unstructured":"Wettersten, H. I., Aboud, O. A., Lara, P. N. Jr. & Weiss, R. H. Metabolic reprogramming in clear cell renal cell carcinoma. Nat. Rev. Nephrol. 13, 410\u2013419 (2017).","journal-title":"Nat. Rev. Nephrol."},{"key":"9277_CR9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","volume":"168","author":"MG Vander Heiden","year":"2017","unstructured":"Vander Heiden, M. G. & DeBerardinis, R. J. Understanding the intersections between metabolism and cancer biology. Cell 168, 657\u2013669 (2017).","journal-title":"Cell"},{"key":"9277_CR10","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1158\/2159-8290.CD-16-0615","volume":"6","author":"C Vernieri","year":"2016","unstructured":"Vernieri, C. et al. Targeting cancer metabolism: dietary and pharmacologic interventions. Cancer Discov. 6, 1315\u20131333 (2016).","journal-title":"Cancer Discov."},{"key":"9277_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nchembio.1986","volume":"12","author":"MG Rees","year":"2016","unstructured":"Rees, M. G. et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat. Chem. Biol. 12, 109\u2013116 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"9277_CR12","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1158\/2159-8290.CD-15-0235","volume":"5","author":"B Seashore-Ludlow","year":"2015","unstructured":"Seashore-Ludlow, B. et al. Harnessing connectivity in a large-scale small-molecule sensitivity dataset. Cancer Discov. 5, 1210\u20131223 (2015).","journal-title":"Cancer Discov."},{"key":"9277_CR13","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.cell.2013.08.003","volume":"154","author":"A Basu","year":"2013","unstructured":"Basu, A. et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 154, 1151\u20131161 (2013).","journal-title":"Cell"},{"key":"9277_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0315-z","author":"H Miess","year":"2018","unstructured":"Miess, H. et al. The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma. Oncogene. https:\/\/doi.org\/10.1038\/s41388-018-0315-z (2018).","journal-title":"Oncogene"},{"key":"9277_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang, W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317\u2013331 (2014).","journal-title":"Cell"},{"key":"9277_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.redox.2016.05.003","volume":"9","author":"BA Carlson","year":"2016","unstructured":"Carlson, B. A. et al. Glutathione peroxidase 4 and vitamin E cooperatively prevent hepatocellular degeneration. Redox Biol. 9, 22\u201331 (2016).","journal-title":"Redox Biol."},{"key":"9277_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.neuint.2017.01.004","volume":"104","author":"SJ Guiney","year":"2017","unstructured":"Guiney, S. J., Adlard, P. A., Bush, A. I., Finkelstein, D. I. & Ayton, S. Ferroptosis and cell death mechanisms in Parkinson\u2019s disease. Neurochem. Int. 104, 34\u201348 (2017).","journal-title":"Neurochem. Int."},{"key":"9277_CR18","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1681\/ASN.2015121376","volume":"28","author":"D Martin-Sanchez","year":"2017","unstructured":"Martin-Sanchez, D. et al. Ferroptosis, but not necroptosis, is important in nephrotoxic folic acid-induced AKI. J. Am. Soc. Nephrol. 28, 218\u2013229 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"9277_CR19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/hep.29117","volume":"66","author":"H Wang","year":"2017","unstructured":"Wang, H. et al. Characterization of ferroptosis in murine models of hemochromatosis. Hepatol. (Baltim., Md.) 66, 449\u2013465 (2017).","journal-title":"Hepatol. (Baltim., Md.)"},{"key":"9277_CR20","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.cell.2017.09.044","volume":"171","author":"SE Wenzel","year":"2017","unstructured":"Wenzel, S. E. et al. PEBP1 Wardens Ferroptosis by Enabling Lipoxygenase Generation of Lipid Death Signals. Cell 171, 628\u2013641.e626 (2017).","journal-title":"Cell"},{"key":"9277_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nature23007","volume":"547","author":"VS Viswanathan","year":"2017","unstructured":"Viswanathan, V. S. et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547, 453\u2013457 (2017).","journal-title":"Nature"},{"key":"9277_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer, M. J. et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551, 247\u2013250 (2017).","journal-title":"Nature"},{"key":"9277_CR23","doi-asserted-by":"crossref","unstructured":"Tsoi, J. et al. Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. Cancer Cell 33, 890\u2013904 (2018).","DOI":"10.1016\/j.ccell.2018.03.017"},{"key":"9277_CR24","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012).","journal-title":"Nature"},{"key":"9277_CR25","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak, A. et al. Defining a Cancer Dependency Map. Cell 170, 564\u2013576.e516 (2017).","journal-title":"Cell"},{"key":"9277_CR26","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/ncb3064","volume":"16","author":"JP Friedmann Angeli","year":"2014","unstructured":"Friedmann Angeli, J. P. et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 16, 1180\u20131191 (2014).","journal-title":"Nat. Cell Biol."},{"key":"9277_CR27","doi-asserted-by":"publisher","first-page":"16836","DOI":"10.1073\/pnas.1415518111","volume":"111","author":"A Linkermann","year":"2014","unstructured":"Linkermann, A. et al. Synchronized renal tubular cell death involves ferroptosis. Proc. Natl Acad. Sci. USA 111, 16836\u201316841 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"9277_CR28","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/path.5037","volume":"244","author":"JX Ji","year":"2018","unstructured":"Ji, J. X., Wang, Y. K., Cochrane, D. R. & Huntsman, D. G. Clear cell carcinomas of the ovary and kidney: clarity through genomics. J. Pathol. 244, 550\u2013564 (2018).","journal-title":"J. Pathol."},{"key":"9277_CR29","doi-asserted-by":"publisher","first-page":"6422","DOI":"10.1158\/1078-0432.CCR-05-0508","volume":"11","author":"KK Zorn","year":"2005","unstructured":"Zorn, K. K. et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 11, 6422\u20136430 (2005).","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"9277_CR30","doi-asserted-by":"publisher","first-page":"e74562","DOI":"10.1371\/journal.pone.0074562","volume":"8","author":"J Cuff","year":"2013","unstructured":"Cuff, J. et al. Integrative bioinformatics links HNF1B with clear cell carcinoma and tumor-associated thrombosis. PLoS One 8, e74562 (2013).","journal-title":"PLoS One"},{"key":"9277_CR31","doi-asserted-by":"publisher","first-page":"343.e349","DOI":"10.1016\/j.urolonc.2018.01.015","volume":"36","author":"K Wang","year":"2018","unstructured":"Wang, K. et al. PLIN3 is up-regulated and correlates with poor prognosis in clear cell renal cell carcinoma. Urol. Oncol. 36, 343.e349\u2013343.e319 (2018).","journal-title":"Urol. Oncol."},{"key":"9277_CR32","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.anndiagpath.2012.10.006","volume":"17","author":"EF Clayton","year":"2013","unstructured":"Clayton, E. F., Ziober, A., Yao, Y. & Bing, Z. Malignant tumors with clear cell morphology: a comparative immunohistochemical study with renal cell carcinoma antibody, Pax8, steroidogenic factor 1, and brachyury. Ann. Diagn. Pathol. 17, 192\u2013197 (2013).","journal-title":"Ann. Diagn. Pathol."},{"key":"9277_CR33","first-page":"137","volume":"53","author":"Q Cao","year":"2018","unstructured":"Cao, Q. et al. Overexpression of PLIN2 is a prognostic marker and attenuates tumor progression in clear cell renal cell carcinoma. Int. J. Oncol. 53, 137\u2013147 (2018).","journal-title":"Int. J. Oncol."},{"key":"9277_CR34","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell, B. R. et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell 171, 273\u2013285 (2017).","journal-title":"Cell"},{"key":"9277_CR35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nchembio.2239","volume":"13","author":"S Doll","year":"2017","unstructured":"Doll, S. et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 13, 91\u201398 (2017).","journal-title":"Nat. Chem. Biol."},{"key":"9277_CR36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.28251","volume":"63","author":"X Sun","year":"2016","unstructured":"Sun, X. et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatol. (Baltim., Md.) 63, 173\u2013184 (2016).","journal-title":"Hepatol. (Baltim., Md.)"},{"key":"9277_CR37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-pathol-012513-104720","volume":"9","author":"GL Semenza","year":"2014","unstructured":"Semenza, G. L. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu. Rev. Pathol. 9, 47\u201371 (2014).","journal-title":"Annu. Rev. Pathol."},{"key":"9277_CR38","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1016\/j.biocel.2010.06.007","volume":"42","author":"PK Ng","year":"2010","unstructured":"Ng, P. K., Yu, R. M., Kwong, T. F., Wong, M. M. & Kong, R. Y. Transcriptional regulation and functional implication of the grass carp CITED1 (gcCITED1) in the negative regulation of HIF-1. Int. J. Biochem. Cell. Biol. 42, 1544\u20131552 (2010).","journal-title":"Int. J. Biochem. Cell. Biol."},{"key":"9277_CR39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.semcancer.2012.06.001","volume":"23","author":"C Shen","year":"2013","unstructured":"Shen, C. & Kaelin, W. G. Jr. The VHL\/HIF axis in clear cell renal carcinoma. Semin. Cancer Biol. 23, 18\u201325 (2013).","journal-title":"Semin. Cancer Biol."},{"key":"9277_CR40","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1158\/2159-8290.CD-14-1507","volume":"5","author":"B Qiu","year":"2015","unstructured":"Qiu, B. et al. HIF2\u03b1-dependent lipid storage promotes endoplasmic reticulum homeostasis in clear-cell renal cell carcinoma. Cancer Discov. 5, 652\u2013667 (2015).","journal-title":"Cancer Discov."},{"key":"9277_CR41","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nm0895-822","volume":"1","author":"O Iliopoulos","year":"1995","unstructured":"Iliopoulos, O., Kibel, A., Gray, S. & Kaelin, W. G. Jr. Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. 1, 822\u2013826 (1995).","journal-title":"Nat. Med."},{"key":"9277_CR42","doi-asserted-by":"publisher","first-page":"E83","DOI":"10.1371\/journal.pbio.0000083","volume":"1","author":"K Kondo","year":"2003","unstructured":"Kondo, K., Kim, W. Y., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1, E83 (2003).","journal-title":"PLoS Biol."},{"key":"9277_CR43","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.humpath.2007.02.010","volume":"38","author":"R Osada","year":"2007","unstructured":"Osada, R. et al. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Hum. Pathol. 38, 1310\u20131320 (2007).","journal-title":"Hum. Pathol."},{"key":"9277_CR44","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.7150\/thno.19988","volume":"7","author":"Y Jiang","year":"2017","unstructured":"Jiang, Y. et al. EGLN1\/c-Myc induced lymphoid-specific helicase inhibits ferroptosis through lipid metabolic gene expression changes. Theranostics 7, 3293\u20133305 (2017).","journal-title":"Theranostics"},{"key":"9277_CR45","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nchembio.2238","volume":"13","author":"VE Kagan","year":"2017","unstructured":"Kagan, V. E. et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat. Chem. Biol. 13, 81\u201390 (2017).","journal-title":"Nat. Chem. Biol."},{"key":"9277_CR46","doi-asserted-by":"publisher","first-page":"E4966","DOI":"10.1073\/pnas.1603244113","volume":"113","author":"WS Yang","year":"2016","unstructured":"Yang, W. S. et al. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc. Natl. Acad. Sci. USA 113, E4966\u2013E4975 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"9277_CR47","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1016\/j.celrep.2018.08.015","volume":"24","author":"D Ackerman","year":"2018","unstructured":"Ackerman, D. et al. Triglycerides promote lipid homeostasis during hypoxic stress by balancing fatty acid saturation. Cell Rep. 24, 2596\u20132605.e2595 (2018).","journal-title":"Cell Rep."},{"key":"9277_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/srep28932","volume":"6","author":"K Saito","year":"2016","unstructured":"Saito, K. et al. Lipidomic signatures and associated transcriptomic profiles of clear cell renal cell carcinoma. Sci. Rep. 6, 28932 (2016).","journal-title":"Sci. Rep."},{"key":"9277_CR49","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M082388","author":"KM Padmanabha Das","year":"2018","unstructured":"Padmanabha Das, K. M. et al. Hypoxia inducible lipid droplet associated protein inhibits adipose triglyceride lipase. J. Lipid Res. 59, 531\u2013541 (2018).","journal-title":"J. Lipid Res."},{"key":"9277_CR50","doi-asserted-by":"crossref","unstructured":"Zhang, X. et al. Inhibition of intracellular lipolysis promotes human cancer cell adaptation to hypoxia. eLife 6, e31132 (2017).","DOI":"10.7554\/eLife.31132"},{"key":"9277_CR51","doi-asserted-by":"publisher","first-page":"s421","DOI":"10.1038\/ng.2204","volume":"44","author":"J Schodel","year":"2012","unstructured":"Schodel, J. et al. Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression. Nat. Genet. 44, s421\u2013s422 (2012).","journal-title":"Nat. Genet."},{"key":"9277_CR52","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1096\/fj.201700235R","volume":"31","author":"A Maier","year":"2017","unstructured":"Maier, A. et al. Hypoxia-inducible protein 2 Hig2\/Hilpda mediates neutral lipid accumulation in macrophages and contributes to atherosclerosis in apolipoprotein E-deficient mice. FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 31, 4971\u20134984 (2017).","journal-title":"FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"9277_CR53","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/IGC.0b013e3181ca1e16","volume":"20","author":"S Nishimura","year":"2010","unstructured":"Nishimura, S. et al. Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas. Int. J. Gynecol Cancer 20, 220\u2013226 (2010).","journal-title":"Int. J. Gynecol Cancer"},{"key":"9277_CR54","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrendo.2014.188","volume":"11","author":"J Favier","year":"2015","unstructured":"Favier, J., Amar, L. & Gimenez-Roqueplo, A. P. Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat. Rev. Endocrinol. 11, 101\u2013111 (2015).","journal-title":"Nat. Rev. Endocrinol."},{"key":"9277_CR55","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature19796","volume":"539","author":"W Chen","year":"2016","unstructured":"Chen, W. et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 539, 112\u2013117 (2016).","journal-title":"Nature"},{"key":"9277_CR56","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature19795","volume":"539","author":"H Cho","year":"2016","unstructured":"Cho, H. et al. On-target efficacy of a HIF-2alpha antagonist in preclinical kidney cancer models. Nature 539, 107\u2013111 (2016).","journal-title":"Nature"},{"key":"9277_CR57","doi-asserted-by":"crossref","unstructured":"Li, J. et al. Lipid desaturation is a metabolic marker and therapeutic target of ovarian cancer stem cells. Cell Stem Cell. 20, 303\u2013314 (2016).","DOI":"10.1016\/j.stem.2016.11.004"},{"key":"9277_CR58","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.cmet.2010.02.003","volume":"11","author":"X Yang","year":"2010","unstructured":"Yang, X. et al. The G(0)\/G(1) switch gene 2 regulates adipose lipolysis through association with adipose triglyceride lipase. Cell. Metab. 11, 194\u2013205 (2010).","journal-title":"Cell. Metab."},{"key":"9277_CR59","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.002333","author":"MA Mitsche","year":"2018","unstructured":"Mitsche, M. A., Hobbs, H. H. & Cohen, J. C. Phospholipase domain-containing protein 3 promotes transfers of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets. J. Biol. Chem. https:\/\/doi.org\/10.1074\/jbc.RA118.002333 (2018).","journal-title":"J. Biol. Chem."},{"key":"9277_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-018-0085-z","author":"JA Olzmann","year":"2018","unstructured":"Olzmann, J. A. & Carvalho, P. Dynamics and functions of lipid droplets. Nat. Rev. Mol. Cell Biol. 20, 137\u2013155 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"9277_CR61","doi-asserted-by":"publisher","unstructured":"Eaton, J. K. et al. Targeting a therapy-resistant cancer cell state using masked electrophiles as GPX4 inhibitors. bioRxiv, https:\/\/doi.org\/10.1101\/376764 (2018).","DOI":"10.1101\/376764"},{"key":"9277_CR62","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1016\/j.bmcl.2011.09.047","volume":"22","author":"M Weiwer","year":"2012","unstructured":"Weiwer, M. et al. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg. & Med. Chem. Lett. 22, 1822\u20131826 (2012).","journal-title":"Bioorg. & Med. Chem. Lett."},{"key":"9277_CR63","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1074\/jbc.M007273200","volume":"276","author":"VC Hannah","year":"2001","unstructured":"Hannah, V. C., Ou, J., Luong, A., Goldstein, J. L. & Brown, M. S. Unsaturated fatty acids down-regulate srebp isoforms 1a and 1c by two mechanisms in HEK-293 cells. J. Biol. Chem. 276, 4365\u20134372 (2001).","journal-title":"J. Biol. Chem."},{"key":"9277_CR64","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nbt.4048","volume":"36","author":"FJ Najm","year":"2018","unstructured":"Najm, F. J. et al. Orthologous CRISPR-Cas9 enzymes for combinatorial genetic screens. Nat. Biotechnol. 36, 179\u2013189 (2018).","journal-title":"Nat. Biotechnol."},{"key":"9277_CR65","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184\u2013191 (2016).","journal-title":"Nat. Biotechnol."},{"key":"9277_CR66","doi-asserted-by":"publisher","first-page":"e0197547","DOI":"10.1371\/journal.pone.0197547","volume":"13","author":"M Hegde","year":"2018","unstructured":"Hegde, M., Strand, C., Hanna, R. E. & Doench, J. G. Uncoupling of sgRNAs from their associated barcodes during PCR amplification of combinatorial CRISPR screens. PLoS One 13, e0197547 (2018).","journal-title":"PLoS One"},{"key":"9277_CR67","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1073\/pnas.1505979112","volume":"112","author":"A Rotem","year":"2015","unstructured":"Rotem, A. et al. Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation. Proc. Natl Acad. Sci. USA 112, 5708\u20135713 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"9277_CR68","first-page":"6012","volume":"46","author":"M Brower","year":"1986","unstructured":"Brower, M. Correspondence re: Martin Brower et al. Growth of Cell Lines and Clinical Specimens of Human Non-Small Cell Lung Cancer in a Serum-free Defined Medium. Cancer Res., 46: 798\u2013806, 1986\u2014Reply. Cancer Res. 46, 6012\u20136012 (1986).","journal-title":"Cancer Res."},{"key":"9277_CR69","first-page":"6011","volume":"46","author":"AF Gazdar","year":"1986","unstructured":"Gazdar, A. F. & Oie, H. K. Correspondence re: Martin Brower et al. Growth of Cell Lines and Clinical Specimens of Human Non-Small Cell Lung Cancer in a Serum-free Defined Medium. Cancer Res., 46: 798\u2013806, 1986. Cancer Res. 46, 6011\u20136011 (1986).","journal-title":"Cancer Res."},{"key":"9277_CR70","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ajpath.2011.10.036","volume":"180","author":"X Liu","year":"2012","unstructured":"Liu, X. et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am. J. Pathol. 180, 599\u2013607 (2012).","journal-title":"Am. J. Pathol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-09277-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-09277-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-09277-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T13:51:19Z","timestamp":1694785879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-09277-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,8]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["9277"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-09277-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,8]]},"assertion":[{"value":"20 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.L.S. is a member of the Board of Directors of the Genomics Institute of the Novartis Research Foundation (GNF); a shareholder and member of the Board of Directors of Jnana Therapeutics; a shareholder of Forma Therapeutics; a shareholder of and adviser to Decibel Therapeutics and Eikonizo Therapeutics; an adviser to Eisai, Inc., the Ono Pharma Foundation, and F-Prime Capital Partners; and a Novartis Faculty Scholar. P.A.C. is an adviser to Pfizer, Inc. S. Signoretti has consulting or advisory role for AstraZeneca\/MedImmune, Merck, AACR, NCI; royalties from Biogenex Laboratories; and research funding from AstraZeneca, Exelixis, Bristol-Myers Squibb. T.K.C. receives institutional and personal research funds from AstraZeneca, Bayer, BMS, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Ipsen, Tracon, Genentech, Roche, Roche Products Limited, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Calithera, Analysis Group, Takeda; and receives personal honoraria from AstraZeneca, Alexion, Sanofi\/Aventis, Bayer, BMS, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group, NCCN, Michael J. Hennessy (MJH) Associates, Inc (Healthcare Communications Company with several brands such as OnClive and PER), L-path, Kidney Cancer Journal, Clinical Care Options, Platform Q, Navinata Healthcare, Harborside Press, American Society of Medical Oncology, NEJM, Lancet Oncology, Heron Therapeutics; and has consulting or advisory role for AstraZeneca, Alexion, Sanofi\/Aventis, Bayer, BMS, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Heron Therapeutics, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group. No speaker\u2019s bureau. No leadership or employment in for-profit companies. Other present or past leadership roles for T.K.C.: Director of GU Oncology Division at Dana-Farber and past President of medical Staff at Dana-Farber), member of NCCN Kidney panel and the GU Steering Committee, past chairman of the Kidney cancer Association Medical and Scientific Steering Committee). No Patents, royalties or other intellectual properties. Travel, accommodations, expenses, in relation to consulting, advisory roles, or honoraria. Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies. The institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or\/and royalties potentially involved in research around the subject matter. CV provided upon request for scope of clinical practice and research. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1617"}}